Summary
On October 18, 2024, the European Commission published Commission Implementing Regulation (EU) 2024/2694, officially authorizing the use of magnesium L-threonate as a novel food ingredient in food supplements intended exclusively for adults. This new regulation permits the use of magnesium L-threonate in food supplements across the EU, with a specified maximum intake of 250 mg per day and with labelling requirements that exclude pregnant and lactating women from its intended audience.
Key Points of the Regulation
- Authorized Use: Magnesium L-threonate is approved solely for adult food supplements with a maximum dose of 250 mg/day.
- Labelling Requirements: Labels must specify “Magnesium L-threonate” and state that the product is intended only for adults, excluding pregnant and lactating women.
- Specifications Compliance: All products must adhere to the specifications outlined in the Annex of the regulation.
- Market Exclusivity: AIDP Inc., the applicant company, holds exclusive rights to market magnesium L-threonate in the EU for five years starting November 7, 2024, with data protection rights as per Article 26(2) of Regulation (EU) 2015/2283.
- EFSA Assessment: The European Food Safety Authority (EFSA) has reviewed magnesium L-threonate and determined it is safe under the specified conditions of use, offering a bioavailable source of magnesium.
Implementation and Deadlines
This regulation will take effect 20 days following its publication in the Official Journal of the European Union.
Subscribe to the latest regulatory news
Curated newsletters
Relevant industry info
Access expert insights